Clinical Trials Directory

Trials / Completed

CompletedNCT00702637

Study of Modafinil to Treat Fatigue in Persons With Traumatic Brain Injury

Modafinil for the Treatment of Fatigue and Excessive Daytime Sleepiness in Individuals With Traumatic Brain Injury

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
60 (planned)
Sponsor
Craig Hospital · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers

Summary

The purpose of this study is to determine whether Modafinil is effective in: (1) reducing fatigue and excessive daytime sleepiness (EDS) in individuals with Traumatic Brain Injury (TBI); and (2) improving cognitive function and quality of life in individuals with TBI.

Detailed description

Background: An estimated 5.3 million Americans are living with a TBI-related disability today. These persons may face many issues, however, two chronic problems seem common to a strikingly large number of those who survive TBI: fatigue and EDS. Need for Research: Modafinil has been shown to be useful for fatigue and sleepiness in patients with depression, multiple sclerosis, Parkinson's disease and individuals with EDS secondary to a variety of sleep disturbances. However, there has not been any controlled evaluation of Modafinil use for the treatment of individuals with TBI to date. Current and Future Research Activity: Approximately 60 participants with post-TBI fatigue will be randomly assigned to two 10-week periods of taking either Modafinil or placebo. Participants taking Modafinil during the first 10 weeks will be switched to placebo for the second 10 weeks. Similarly, participants taking placebo during the first 10 weeks will be switched to Modafinil for the second 10 weeks. Outcomes relating to fatigue and EDS will be collected weekly throughout the study. Other outcomes (including general health, depression, and cognitive function) will be collected at the start of each period, 4 weeks into each period, and again at the end of each period. It is hypothesized that participants taking Modafinil will report significantly less fatigue and EDS, report significantly better general health and depression scores, and perform significantly better on tests of cognitive performance in comparison to participants taking placebo.

Conditions

Interventions

TypeNameDescription
DRUGModafinil

Timeline

Start date
2002-10-01
Primary completion
2005-03-01
Completion
2005-03-01
First posted
2008-06-20
Last updated
2010-06-14

Source: ClinicalTrials.gov record NCT00702637. Inclusion in this directory is not an endorsement.

Study of Modafinil to Treat Fatigue in Persons With Traumatic Brain Injury (NCT00702637) · Clinical Trials Directory